Cretostimogene reduces NMIBC recurrence risk by 68% in Phase 3 PIVOT-006, company reports
Phase 3 RCT · Dealroom · 2026-11-16. Number 2 in the UrologyWatch Top 5 for November 17, 2026.
CG Oncology announced topline results from its Phase 3 PIVOT-006 trial, reporting that cretostimogene reduced recurrence risk by 68% in NMIBC patients, with no patients discontinuing treatment due to related side effects. Full data and statistical details have not yet been disclosed.
Why it matters: A company-reported Phase 3 topline result suggests cretostimogene may offer a new intravesical option for NMIBC, pending full data disclosure and FDA review.
Source: Dealroom
Loading today's edition…